as 07-01-2025 3:38pm EST
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
Founded: | 2017 | Country: | United States |
Employees: | 8 | City: | SAN MATEO |
Market Cap: | 54.1M | IPO Year: | 2020 |
Target Price: | $1.63 | AVG Volume (30 days): | 1.4M |
Analyst Decision: | Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.07 | EPS Growth: | N/A |
52 Week Low/High: | $0.65 - $1.60 | Next Earning Date: | 08-07-2025 |
Revenue: | $9,192,000 | Revenue Growth: | 21.16% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
KNOBELMAN DEBORAH | KRON | President & Interim CEO | Jun 5 '25 | Sell | $0.87 | 24,838 | $21,554.42 | 139,422 |
KRON Breaking Stock News: Dive into KRON Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
GlobeNewswire
2 months ago
Simply Wall St.
3 months ago
GlobeNewswire
3 months ago
Simply Wall St.
4 months ago
Simply Wall St.
6 months ago
MT Newswires
6 months ago
Simply Wall St.
7 months ago
The information presented on this page, "KRON Kronos Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.